Figma Shares Indicated To Open $105/$110
In a recent SEC filing, Campbell Bradley L., President and CEO of Amicus Therapeutics Inc. (NASDAQ:FOLD), a biotechnology company with an impressive 90% gross profit margin and $2.75 billion market capitalization, reported a series of transactions involving the company’s common stock. On February 19, Bradley sold 400 shares at a price of $10.00 each, totaling $4,000.
Additionally, Bradley exercised stock options to acquire 400 shares at a price of $9.03 per share, with a total transaction value of $3,611. These transactions were conducted under a pre-established Rule 10b5-1 trading plan adopted on September 13, 2024. Following these transactions, Bradley’s direct ownership stands at 1,150,657 shares.
In other recent news, Amicus Therapeutics reported a significant year-over-year revenue increase for 2024, reaching $528.3 million, with Galafold sales climbing to $458.2 million. The company also anticipates achieving positive GAAP net income in the second half of the year. BofA Securities adjusted its price target for Amicus Therapeutics to $14 from $15, while maintaining a Buy rating, reflecting confidence in the company’s future prospects. Meanwhile, Goldman Sachs reiterated a Neutral rating with a $14 price target, highlighting the potential for revenue growth through Galafold exclusivity and Pombiliti+Opfolda sales. Morgan Stanley (NYSE:MS) downgraded Amicus Therapeutics from Overweight to Equalweight, reducing the price target to $12.00, citing a need for new growth drivers. Additionally, Amicus filed a prospectus supplement for its at-the-market stock program, ensuring the flexibility to sell shares in the future. The company’s recent performance and strategic decisions indicate a focus on maintaining financial stability and exploring long-term growth opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.